Vaxcyte, Inc. (PCVX)
- Sector
- Biotechnology
- Last price
- $59.40
- As of
Kresmion compiles this page from PCVX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Vaxcyte, Inc. (PCVX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.
See the full PCVX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PCVX on one page. Preview it with sample data, then open it live with a free account.
Preview the PCVX dossierActive events for PCVX
- mediumEarnings above estimates
Q3-2026: Beat consensus by 8.5%, EPS $-1.99 vs $-2.1749 estimate
- high13F: funds added
4 tracked funds increased PCVX this 2026Q2, institutional consensus
- high13F: funds added
3 tracked funds increased PCVX this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +293% to PCVX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +304% to PCVX (2026Q2)
FREE, NO ACCOUNT
Every event on PCVX, as it fires
You are seeing 5 of 15 events recorded on PCVX since 2026-06-02.
The five above landed across 3 days. The other 10 were recorded on 3 other days. 8 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, PCVX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on PCVX
PCVX against its peers
PCVX's return on equity of -28.5% ranks in the 45th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-09-30.
| Metric | PCVX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 190M | n/a | 17 |
| Gross margin | n/a | 83.7% | n/a | 7 |
| Operating margin | n/a | -101.2% | n/a | 15 |
| Net margin | n/a | -103.6% | n/a | 15 |
| Return on equity | -28.5% | -22.0% | 45 | 20 |
| P / E | n/a | 32.5x | n/a | 5 |
| 1 year | 26.7% | 47.1% | 40 | 20 |
Peers (23): NUVL.D, MDGL, TGTX, SMMT, SYRE, APGE.D, CRNX.D, KYMR, KRYS, PRAX, HALO, BMRN, PTGX, CYTK, RYTM, ALKS, ABVX, CAI, ORKA, KOD, CGON, ARWR, IBRX. Left out: SBMFF (no annual filing), BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-09-30. Every figure is one full fiscal year read from one annual filing (PCVX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in PCVX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PCVX in the last 180 days.
Upstream: SEC EDGAR filings for PCVX
Kresmion, "Vaxcyte, Inc. (PCVX) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/PCVX. Upstream data: SEC EDGAR filings for PCVX.
Link to this data (HTML):
<a href="https://kresmion.com/research/PCVX">Vaxcyte, Inc. (PCVX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow PCVX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PCVX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.